Introduction
============

Through its reversible attachment to intracellular proteins the small ubiquitin-related modifier SUMO controls numerous biological processes, ranging from nucleo-cytoplasmic transport to the regulation of transcription and the maintenance of genome stability ([@b17]; [@b7]). Modification by SUMO follows a mechanism closely related to that used by the ubiquitin system: the modifier\'s carboxy terminus is activated by a dedicated activating enzyme (E1), transferred to a conjugating enzyme (E2) and linked to a lysine residue of the substrate protein with the aid of a ligase (E3) that confers selectivity to the reaction. In the SUMO system, however, the single E2, Ubc9, often participates directly in substrate recognition, and some SUMO-specific E3s, such as mammalian RanBP2, stimulate the conjugation reaction in a substrate-independent manner by aligning the SUMO thioester on the Ubc9 active site in a conformation favourable for attack by an incoming lysine ([@b28]). As a consequence, *in vitro* sumoylation reactions tend to be highly promiscuous, and even *in vivo* many substrates can be sumoylated by more than one E3 ([@b27]). Selectivity and spatio-temporal control over the modification can sometimes be attributed to signalling cascades resulting in the phosphorylation of the E3 or the substrate, but more often the dynamic regulation of sumoylation is poorly understood ([@b9]).

In eukaryotic cells, post-translational modifications of the replicative sliding clamp PCNA control the processing of replication intermediates ([@b33]). In response to DNA damage, ubiquitylation of PCNA promotes the bypass of replication-blocking lesions ([@b12]; [@b29]; [@b16]). In budding yeast, PCNA (encoded by *POL30*) is also subject to damage-independent sumoylation during S phase, which enhances its affinity for an antirecombinogenic helicase, Srs2 ([@b25]; [@b26]). Recruitment of Srs2 by the modified clamp prevents unscheduled recombination events during replication. When progression of replication forks is stalled by DNA damage, Srs2 thus inhibits resolution by homologous recombination and allows damage bypass via the ubiquitin-dependent pathway. Sumoylation of PCNA occurs on two lysines, predominantly on K164 and to a lesser extent on K127. Modification at K164 *in vivo* and *in vitro* requires the E3 Siz1, but Siz1 also stimulates non-selective sumoylation at K127 and the formation of poly-SUMO chains on PCNA ([@b12]; [@b29]; [@b34]). During most of the cell cycle, Siz1 is nuclear, with the exception of G2/M phase, when the E3 associates with the bud neck and participates in septin sumoylation ([@b14]; [@b32]). A conserved SAP domain, which often binds DNA in other proteins ([@b23]; [@b22]), determines nuclear localisation or retention ([@b30]) and was found to be required for PCNA modification ([@b27]). SUMO is removed from PCNA by the isopeptidase Ulp1, which associates with nuclear pore complexes throughout the cell cycle ([@b19]; [@b24]; [@b29]).

Under physiological conditions, sumoylation of PCNA is limited to S phase, but it is unclear how this is controlled. We have therefore investigated the signals required for Siz1-dependent modification of PCNA *in vivo*. To our surprise, we found that SUMO conjugation to PCNA is governed less by the cognate enzymes than by the properties of the clamp itself, in particular its association with DNA. This mechanism of PCNA modification is accurately reproduced by a recombinant *in vitro* system and suggests a substrate-induced control over sumoylation.

Results
=======

PCNA sumoylation is controlled by conjugation and de-conjugation
----------------------------------------------------------------

To understand whether regulation of conjugation by Siz1 or of de-conjugation by Ulp1 was primarily responsible for the restriction of PCNA sumoylation to S phase, we analysed the cell cycle dependence of the modification in the relevant mutants ([Figure 1A and B](#f1){ref-type="fig"}). Synchronised cultures of *ulp1*^*ts*^ cells initiated sumoylation in S phase, but due to the slower cell cycle progression, the modification persisted throughout the experiment. The marked upregulation of sumoylation upon entry into S phase even under conditions where de-conjugation is compromised suggested that the cell cycle influences the conjugation reaction. As expected, sumoylation at K164 was abolished in the *siz1* mutant. Surprisingly, however, sumoylation at K127 still fluctuated with the cell cycle in this mutant, indicating that Siz1 alone cannot be responsible for upregulating PCNA sumoylation. To assess whether modification at K127 was mediated solely by Ubc9 or depended on a second E3, we deleted *SIZ2* in addition to *SIZ1*, and now conjugation was completely abolished. Therefore, S phase-specific sumoylation of PCNA is not strictly dependent on its cognate E3, Siz1, but can also be performed by the closely related Siz2 enzyme, albeit with lower efficiency and on a different lysine.

These data indicate that both conjugation and de-conjugation contribute to limiting PCNA sumoylation to S phase. However, the cell cycle-dependent fluctuation of the modification is unlikely to be regulated simply by a balance of the respective conjugating and de-conjugating enzymes in the nucleus: first, Siz2---unlike Siz1---remains nuclear in G2 ([@b31]), yet Siz2-dependent sumoylation is lost at this time in *siz1* mutants. Second, PCNA is not sumoylated in G1 despite its colocalisation with Siz1 and Siz2 in the nucleus. Therefore, selective modification in S phase appears to require cell cycle-dependent changes in either enzyme activities or substrate properties.

PCNA sumoylation *in vivo* correlates with its loading onto DNA
---------------------------------------------------------------

In response to lethal concentrations of the alkylating agent methyl methanesulphonate (MMS), PCNA is strongly sumoylated in a Siz1-dependent manner ([@b12]; [@b34]). We found that this reaction was independent of the cell cycle stage ([Figure 1C](#f1){ref-type="fig"}). Hence, given the appropriate signal, sumoylation of PCNA is not limited to S phase. We reasoned that the extraordinary levels of DNA damage inflicted by this treatment would likely cause an enhanced engagement of PCNA in repair activities and therefore a significant association with DNA even outside of S phase. Indeed, chromatin-binding assays after 0.3% MMS treatment revealed strongly elevated amounts of PCNA in the chromatin-bound fraction in an S phase-independent manner ([Figure 1D](#f1){ref-type="fig"}). The observed correlation between PCNA hyper-sumoylation and chromatin association therefore suggested that loading onto DNA might exert an effect as a signal for PCNA sumoylation in undamaged cells as well. This notion was also supported by the sumoylation defect of the PCNA mutant encoded by the *pol30-52* allele ([Figure 1C](#f1){ref-type="fig"}), which is known for poor loading onto DNA due to reduced trimer stability ([@b1]).

If loading were indeed a prerequisite for sumoylation, preventing PCNA association with DNA during S phase should in turn result in a failure to be modified. We therefore examined PCNA sumoylation in a temperature-sensitive *cdc7*^*ts*^ mutant. *CDC7* encodes an essential protein kinase required for the firing of replication origins ([@b11]). Upon release from G1 arrest at the restrictive temperature, *cdc7*^*ts*^ cells do not initiate DNA replication, although budding pattern and cyclin-dependent kinase activities all resemble a passage through the cell cycle. We found that under these conditions, PCNA was not sumoylated ([Figure 2A](#f2){ref-type="fig"}) at a time when the levels of the mitotic cyclin Clb2 ([Figure 2A](#f2){ref-type="fig"}) and the budding pattern ([Figure 2B](#f2){ref-type="fig"}) indicated an S phase-like state. Siz1 was nuclear at this stage and accumulated at the bud neck only in G2/M phase ([Figure 2B](#f2){ref-type="fig"}), when *cdc7*^*ts*^ cells were arrested due to a failure to undergo mitosis with an unreplicated genome. We excluded the formal possibility that the kinase activity of Cdc7 was required for PCNA sumoylation by confirming the modification in a *cdc7* deletion mutant, using a strain background in which *CDC7* was rendered non-essential by a mutation in *MCM5*, a subunit of the replicative helicase ([@b10]) ([Figure 2C](#f2){ref-type="fig"}). Therefore, ongoing DNA replication rather than a particular cell cycle regulatory programme appears to bring about PCNA sumoylation, strongly suggesting that the clamp is modified only when it encircles DNA.

PCNA loading stimulates sumoylation *in vitro*
----------------------------------------------

We have previously demonstrated Siz1-dependent *in vitro* sumoylation of PCNA in the absence of DNA ([@b34]), but if clamp loading were the main prerequisite for modification *in vivo*, association with DNA would also stimulate the reaction *in vitro*. Loading of PCNA is ATP dependent and requires replication factor C (RFC), which opens the PCNA ring and positions the clamp around the DNA at nicks within double-stranded (ds)DNA or 3′ junctions of a primer terminus and single-stranded (ss)DNA ([@b21]). After loading, PCNA can move freely on DNA, but cannot slide off a circular structure. We therefore examined the effect of purified RFC in the presence of multiply primed circular ssDNA at substrate concentrations that yielded barely detectable levels of Siz1-dependent modification in the absence of DNA. As shown in [Figure 3A](#f3){ref-type="fig"}, addition of DNA and RFC strongly stimulated the reaction. Importantly, neither RFC nor DNA alone enhanced SUMO conjugation, indicating that clamp loading rather than ring opening or the mere presence of DNA was important for stimulation. The same effect was observed with a linear biotinylated DNA containing a 3′ junction, provided that its ends were blocked by the addition of streptavidin ([Figure 3B](#f3){ref-type="fig"}). As RFC-dependent loading occurs in the presence or absence of streptavidin, this result implies that a stable DNA-bound state rather than the process of loading determines the efficiency of PCNA sumoylation. Consistent with the loading defect, modification of the mutant protein encoded by *pol30-52* was not stimulated by RFC ([Figure 3C](#f3){ref-type="fig"}), whereas DNA-independent sumoylation at higher protein concentration proceeded with an efficiency comparable to the *WT* ([Figure 3D](#f3){ref-type="fig"}). This again indicates that PCNA needs to encircle DNA as a trimer to be sumoylated efficiently.

Siz1 binds dsDNA by means of a SAP domain
-----------------------------------------

Given that Siz1 contains a SAP domain required for PCNA sumoylation ([@b27]), it appeared likely that the enhanced modification of loaded PCNA was attributable to DNA binding of the E3. We therefore asked whether budding yeast Siz1, similar to other members of the PIAS family, was indeed a DNA-binding protein. Recombinant full-length Siz1 was efficiently retained on a biotinylated 76-bp fragment of dsDNA ([Figure 4A and B](#f4){ref-type="fig"}). Its affinity for a 25-bp dsDNA was significantly reduced, and no signal was detected with a 15-bp fragment. Interestingly, binding was strictly limited to dsDNA. Siz1 did not exhibit enhanced affinity for ss--dsDNA junctions or tailed structures when compared with linear dsDNA ([Figure 4C](#f4){ref-type="fig"}), suggesting that the protein primarily recognises ordinary dsDNA. To confirm the importance of the SAP domain for DNA binding, we constructed two Siz1 mutants: *SAP\**, by mutating three conserved residues within the SAP domain (G55A/K57A/L60A), and *SAP*Δ, by deleting residues 34--68. The purified proteins had no detectable affinity for the 76-bp dsDNA ([Figure 4D](#f4){ref-type="fig"}), indicating that the SAP domain is required for DNA binding.

The Siz1 SAP domain is dispensable for PCNA sumoylation
-------------------------------------------------------

Consistent with previous observations ([@b27]), deletion of the SAP domain resulted in loss of sumoylation at K164 *in vivo*, whereas the *SAP\** mutation had a partial effect ([Figure 5A](#f5){ref-type="fig"}). This pattern was mirrored in a genetic assay based on suppression of the DNA damage sensitivity of *rad18* mutants by loss of *SIZ1* function ([@b29]) ([Figure 5B](#f5){ref-type="fig"}). The PCNA sumoylation defect of *siz1(SAP*Δ) had previously been attributed to a defect in nuclear localisation or retention, possibly due to a lack of Siz1 association with the chromatin ([@b27]). However, western blot analysis of the mutated Siz1 proteins marked with a 9myc-epitope revealed strongly reduced signals for *SAP*^\*^ and in particular for *SAP*Δ in total cell extracts, implying that the lack of activity towards PCNA *in vivo* might be due to insufficient protein rather than ineffective nuclear localisation or defective DNA binding ([Figure 5C](#f5){ref-type="fig"}). In fact, overexpression of the mutants from a galactose-inducible promoter completely rescued the sumoylation defect of *SAP*^\*^ and *SAP*Δ ([Figure 5D](#f5){ref-type="fig"}) and fully restored the damage sensitivity of *rad18* cells ([Figure 5E](#f5){ref-type="fig"}). To exclude the possibility that overproduction of the mutant Siz1 proteins compensated for a loss in activity, we placed the *SAP*Δ allele under control of the copper-inducible *CUP1* promoter, which resulted in protein levels comparable to *WT* Siz1 under control of its native promoter ([Figure 5F](#f5){ref-type="fig"}). In the presence of copper sulphate, this construct almost completely rescued the phenotype of the *siz1* deletion with respect to DNA damage sensitivity ([Figure 5G](#f5){ref-type="fig"}) and PCNA sumoylation ([Figure 5H](#f5){ref-type="fig"}). This indicates that DNA binding of Siz1 might not be a prerequisite for efficient modification of PCNA *in vivo*.

Loading onto DNA changes the properties of PCNA as a sumoylation target
-----------------------------------------------------------------------

To directly compare the activities of the mutant proteins towards PCNA, we analysed their effects on PCNA sumoylation *in vitro* at a range of concentrations. In the absence of DNA, the activities of *SAP\** and *SAP*Δ were slightly lower than those of *WT* Siz1, and selectivity for K164 was somewhat reduced, possibly indicating some destabilisation of the mutant proteins ([Figure 6A](#f6){ref-type="fig"}). Towards loaded PCNA, both mutants were less active than the *WT* protein; in particular, formation of poly-SUMO chains was reduced compared with the *WT* ([Figure 6B](#f6){ref-type="fig"}). Nevertheless, conjugation at K164 by the Siz1 mutants was strongly stimulated by RFC-dependent PCNA loading, indicating that DNA binding of the E3 is not primarily responsible for the effect of PCNA loading on conjugation efficiency. Similar results were obtained with a truncated construct, Siz1(1--508), and its corresponding SAP domain mutants, although the differences in DNA-independent activities between the *WT* and the SAP domain mutants were even more pronounced (see [Supplementary Figure S1](#S1){ref-type="supplementary-material"}).

The notion that even Siz1 mutants defective in DNA binding preferentially modify PCNA when the clamp encircles DNA raised the question of whether stimulation of the reaction could be ascribed primarily to DNA-induced changes in the substrate rather than a proximity effect mediated by the binding of substrate and E3 to a common stretch of DNA. We therefore examined whether PCNA modification in the absence of Siz1 was also influenced by DNA. [Figure 6C](#f6){ref-type="fig"} shows *in vitro* sumoylation of PCNA in the presence of primed DNA as before, but at higher Ubc9 concentrations. Surprisingly, RFC stimulated Ubc9-dependent sumoylation at K127 even in the absence of Siz1 (see also [Supplementary Figure S2](#S1){ref-type="supplementary-material"}). As we were unable to detect any physical interactions between Ubc9 and either DNA or RFC under our experimental conditions (data not shown), we consider an indirect recruitment of Ubc9 to PCNA unlikely and favour a model in which PCNA itself, when loaded onto DNA, becomes a better substrate for sumoylation.

The inner surface of the PCNA ring is lined by several conserved basic residues, which are likely to directly contact DNA ([@b5]; [@b18]; [@b13]) and might therefore influence the conformation of loaded PCNA. Indeed, the respective mutants poorly stimulate polymerase δ, although loading and sliding are not affected ([@b5]; [@b18]). When we examined PCNA sumoylation in two of these alleles, *pol30(K20A)* and *pol30(K77A)*, we found significant defects, in particular in *pol30(K20A)*, which affects a lysine predicted to interact with bound DNA close to the centre of the minor groove ([@b13]) ([Figure 6D](#f6){ref-type="fig"}). Growth and cell cycle distribution of the corresponding cultures were normal, indicating that the defects in PCNA sumoylation were not due to replication problems ([Figure 6E](#f6){ref-type="fig"}). These observations are consistent with a change in conformation and/or flexibility of PCNA upon DNA binding that is transmitted from the inner surface to the outer rim of the clamp, where it is sensed by the sumoylation system.

Discussion
==========

Control of PCNA sumoylation by Siz1 and Ulp1
--------------------------------------------

Our findings suggest an effective mechanism by which SUMO conjugation can be targeted to S phase. We have shown that the overall levels of SUMO-modified PCNA are influenced both by Siz1-dependent conjugation and by Ulp1-mediated de-conjugation. Yet, a cell cycle-dependent fluctuation of sumoylation is observed even when the relevant enzymes are defective, suggesting that changes in enzyme properties or localisation are not primarily responsible for the temporal control of PCNA modification. Instead, we found that sumoylation of PCNA *in vivo* prevailed whenever the clamp was associated with DNA. Considering that even in replicating cells a significant part of the cellular pool of PCNA is not bound to DNA ([@b3]), the total extent of PCNA sumoylation in synchronised cultures ([Figure 1A](#f1){ref-type="fig"}) actually suggests that a major proportion of DNA-loaded PCNA is modified in S phase. Consistent with these observations, we found that the efficiency of PCNA sumoylation *in vitro* is influenced only to some degree by DNA binding of the E3, but more importantly by the stable loading of the clamp onto DNA. Taken together, S phase-associated sumoylation therefore appears to be triggered mainly by a change in the properties of PCNA induced by RFC-dependent loading.

We cannot exclude a minor contribution of cell cycle-dependent changes in E3 or Ulp1 activity to the regulation of PCNA sumoylation. For example, the re-localisation of Siz1 from the nucleus to the bud neck at mitosis is likely due to its cell cycle-regulated phosphorylation ([@b14]) and may well affect the efficiency of PCNA sumoylation at that time. However, given that loading stimulates the reaction with recombinant proteins *in vitro*, and loaded PCNA can be modified outside of S phase *in vivo*, a change in substrate properties is sufficient to explain our observations. According to this model, Ulp1-dependent desumoylation of PCNA at the end of S phase could be induced either by a shift in the balance between conjugation and de-conjugation upon unloading or alternatively by an enhanced exposure of 'soluble\' PCNA to the nuclear pore-associated Ulp1. The regulation of PCNA modification thus exemplifies how dynamic control in the SUMO system can be achieved at the substrate level despite the limited number and selectivity of conjugation factors.

Independent signals for PCNA sumoylation and ubiquitylation
-----------------------------------------------------------

In analogy to the system described here, ubiquitylation of PCNA by the E3 Rad18 was shown to be limited to the DNA-bound form both *in vivo* and *in vitro* ([@b6]; [@b2]). In this case, recruitment of Rad18 by the ssDNA-binding replication protein A (RPA) was found to be required for ubiquitylation *in vivo* ([@b2]). In contrast, depletion of RPA does not affect PCNA sumoylation ([@b2]), and *in vitro* sumoylation of loaded PCNA proceeds efficiently in the absence of RPA. Hence, although the two modifications affect the same site on PCNA, they are initiated in response to independent signals: whereas ubiquitylation is rendered damage inducible by a dependence on the accumulation of RPA-coated ssDNA at stalled replication intermediates, the sumoylation enzymes react primarily to the loading state of the clamp itself and thereby exert an effect constitutively during S phase.

SUMO conjugation as a probe for the conformation of PCNA
--------------------------------------------------------

Our observations provide evidence for a conformational change of the clamp upon loading. This concept has been postulated based on molecular dynamics simulations ([@b13]), but has not been demonstrated experimentally due to the difficulties associated with analysing interactions of a topological rather than an affinity-based nature. Interactions between PCNA and several other replication proteins are well known to be affected by DNA. For example, polymerase δ is stimulated only by DNA-bound PCNA, and the productive mode of interaction between PCNA and the flap endonuclease FEN-1 that occurs on DNA differs from that observed in solution ([@b20]; [@b15]; [@b8]). However, as both polymerase δ and FEN-1 are DNA-binding proteins themselves, their stimulation by loaded PCNA might be due to their own rearrangement on DNA rather than a conformational change of the clamp. This is unlikely to apply to Ubc9; yet the E2 is able to differentiate between loaded and unloaded PCNA. Hence, the sensitivity of the SUMO conjugation system to the loading state of PCNA demonstrates for the first time that contacts between the DNA and the basic inner surface of the clamp can have an impact on residues situated on the outer edge. Changes in the properties of PCNA may well affect its interactions with other replication- or repair-associated proteins. For example, a contribution of conformational changes within PCNA itself to Rad18-dependent ubiquitylation cannot be excluded until a ligase mutant deficient in DNA binding is examined. A detailed understanding of the nature of these conformational changes will have to await the structural characterisation of PCNA in complex with DNA.

Materials and methods
=====================

Yeast strains
-------------

Standard procedures were followed for the growth and manipulation of *Saccharomyces cerevisiae*. Mutants *ulp1*^*ts*^, *siz1, rad18, cdc7*^*ts*^, *bob1* and *bob1 cdc7*Δ have been described previously ([@b25]; [@b2]; [@b34]). Where required, the ^*His*^*POL30* allele was introduced as described ([@b29]; [@b34]), and ^*His*^*pol30(K20A)* and ^*His*^*pol30(K77A)* were constructed analogously. *SIZ2* was deleted by replacement with a *KanMX6* cassette. The *pol30-52* allele was introduced on a centromeric plasmid, pBL230-52 ([@b1]), followed by disruption of endogenous *POL30*. The *SIZ1* alleles were expressed in *siz1* deletion strains from integrative plasmids under control of the endogenous or the *GAL1* or the *CUP1* promoter (see below). For detection by western blotting, these alleles were marked with a 9myc-epitope by integration of a PCR-amplified cassette in place of the stop codon.

Plasmids
--------

The yeast expression vector for ^*His*^*POL30* has been described previously ([@b25]; [@b2]; [@b34]), and mutations K20A and K77A were introduced by site-directed mutagenesis. pBL230-52 was a gift from P Burgers ([@b1]). Recombinant ^His^PCNA was expressed in *Escherichia coli* from pQE-30 ([@b34]), and mutant alleles were constructed in the same vector. pET11c (Novagen) served for expression of recombinant untagged PCNA. Yeast expression vector p416-Siz1-GFP was a gift from E Johnson ([@b14]). For expression of native *SIZ1* in yeast, the open reading frame with 535 bp of its upstream region was amplified from genomic DNA and inserted into the integrative vector YIplac211, followed by a transcriptional terminator. Mutant alleles were constructed by PCR. The *SIZ1* upstream region was replaced by the yeast *GAL1* or *CUP1* promoter for galactose- or copper-inducible expression, respectively. The *E. coli* expression vector for ^GST^Siz1^FLAGHis^ has been described ([@b34]), and the SAP domain mutants were transferred into this construct. An expression vector for yeast RFC was a gift from P Burgers ([@b4]), those for recombinant ^His^Aos1, Uba2^His^, Ubc9^His^ and ^His^SUMO were from E Johnson ([@b14]).

Protein purifications
---------------------

Recombinant ^His^PCNA, E1 (^His^Aos1/Uba2^His^), Ubc9^His^, ^His^SUMO, RFC and ^GST^Siz1^FLAGHis^ were produced as previously described ([@b4]; [@b34]). The Siz1 SAP domain mutants were expressed and purified by the same procedure as the *WT* protein. Mutant PCNA proteins were produced as His~6~-tagged constructs and purified similar to *WT* ^His^PCNA.

Untagged PCNA was produced from the expression vector pET11c in *E. coli* strain BL21-CodonPlus(DE3)-RIL (Stratagene). The bacterial pellet from a 2 l culture was re-suspended in buffer A (25 mM Tris pH 7.5, 1 mM EDTA, 0.5 mM DTT) containing 50 mM NaCl and Complete™ protease inhibitors (Roche) and lysed by sonication. All steps were carried out at 4°C. The lysate was cleared by centrifugation at 40 000 *g* for 20 min and then at 150 000 *g* for 45 min. Nucleic acids were removed by Polymin P precipitation, and the lysate was subjected to HiTrap Q chromatography. PCNA-containing fractions were dialysed into buffer A containing 40 mM NaCl and passed through a 5 ml S-Sepharose column. Following MonoQ chromatography (1 ml column), PCNA-containing fractions were pooled and applied to a Superdex 200 gel filtration column equilibrated in buffer A containing 200 mM NaCl and 10% glycerol. The purified protein was stored at −80°C.

Detection of PCNA modifications *in vivo*
-----------------------------------------

*In vivo* PCNA modifications were detected by denaturing Ni-NTA affinity chromatography and western blot analysis as described previously, using PCNA- and SUMO-specific antibodies ([@b25]; [@b2]). After treatment with 0.3% MMS, sumoylated PCNA was detected in total cell extracts. Cells were arrested in G1, S or G2 phase with 10 ng/ml α-factor, 100 mM hydroxyurea or 15 μg/ml nocodazole for 1.5--3 h, respectively. Cell cycle stage was monitored by flow cytometry. For induction of the *GAL1* promoter, cells were pre-grown in a medium containing 2% raffinose, transferred to 2% galactose medium for overnight growth, and diluted into fresh galactose medium to obtain exponential cultures. Induction of the *CUP1* promoter was achieved by overnight growth in 100 μM CuSO~4~. Control cultures were obtained analogously by transfer and dilution into glucose or copper-free medium.

*In vitro* PCNA sumoylation assays
----------------------------------

*In vitro* sumoylation assays without DNA were performed as previously described ([@b34]). For reactions in the presence of DNA, 10 oligonucleotides of 28--35 nt length were annealed to ΦX174 virion DNA (New England Biolabs) spaced roughly equally along the sequence (DECAprimed DNA). Unless otherwise noted, sumoylation reactions (20 μl) contained 50 mM HEPES, pH 7.0, 140 mM NaCl, 5 mM MgCl~2~, 0.1 mM DTT, 1 mM ATP, 2.5 nM DECAprimed DNA, 50 nM PCNA or ^His^PCNA, 30 nM RFC, 200 nM E1, 500 nM Ubc9^His^ and 8 μM ^His^SUMO. Siz1 was added at a final concentration of ∼25 nM or titrated in the range of ∼1--40 nM ([Figure 6A and B](#f6){ref-type="fig"}). Reactions in the presence of linear DNA were set up as described above, but contained 25 nM biotinylated primed or unprimed DNA, 18 nM RFC and 1 mM streptavidin where noted. Reactions were incubated at 30°C for 2 h before being terminated by the addition of reducing SDS loading buffer and denaturation at 95°C for 4 min. Samples were analysed by western blotting using an anti-PCNA antibody. PCNA and ^His^PCNA were modified with equal efficiency in these assays (data not shown).

*In vitro* DNA-binding assays
-----------------------------

A DNA fragment of a given structure, consisting of either a ss 5′-biotinylated oligonucleotide or an annealed pair of oligonucleotides, one of which carried a 5′-biotin label, was immobilised on streptavidin Sepharose in binding buffer (0.1 mg/ml BSA, 50 mM Tris--HCl, pH 7.5, 10 mM MgCl~2~ or 1 mM EDTA, 1 mM DTT, 0.05% Triton X-100, 150 mM NaCl) for 30 min at room temperature. The beads were washed three times with binding buffer before use. Binding of Siz1 was analysed by incubation of 20 μl beads (∼10 pmol of DNA) with increasing amounts of ^GST^Siz1^FLAGHis^ ([Figure 4A and B](#f4){ref-type="fig"}: 2 and 8 pmol; [Figure 4C](#f4){ref-type="fig"}: 2, 4, 8 and 15 pmol; [Figure 4D](#f4){ref-type="fig"}: 4 and 12 pmol) for 60 min at 4°C. The beads were washed four times with binding buffer, and bound material was eluted by denaturation in SDS loading buffer and detected by western blotting with anti-FLAG antibody.

Chromatin-binding assays
------------------------

Total cell extracts prepared by spheroplast lysis were fractionated into soluble and chromatin-bound fractions by centrifugation through a sucrose cushion and analysed by Western blotting as described previously ([@b2]).

Fluorescence microscopy
-----------------------

*WT* or *cdc7*^*ts*^ cells harbouring p416-Siz1-GFP ([@b14]) were grown to exponential phase in galactose medium at 25°C and treated as described in the legend of [Figure 2](#f2){ref-type="fig"}. Samples were withdrawn at 20-min intervals, and DNA was stained with 0.5 μg/ml 4′,6-diamidino-2-phenylindole (DAPI). Cells were analysed by fluorescence microscopy on a DeltaVision Spectris™ system for DAPI and GFP signals. Fluorescence images were processed and overlayed with differential interference contrast images using the Improvision™ software.

Genetic analysis of SIZ1 function
---------------------------------

Growth of yeast strains harbouring relevant *SIZ1* alleles in a *rad18* background was monitored on plates containing various types and concentrations of DNA-damaging agents, using *WT, rad18, siz1* and *rad18 siz1* as control strains. Loss of *SIZ1* function is indicated by a partial suppression of the damage sensitivity associated with the *rad18* deletion ([@b25]; [@b34]). For analysis of *GAL1*- or *CUP1*-inducible *SIZ1* alleles, cultures were pregrown in liquid glucose or galactose medium or in the presence or absence of 100 μM CuSO~4~ and analysed on plates containing the corresponding carbon source or copper concentration.
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![Cell cycle- and DNA damage-dependent sumoylation of PCNA. (**A**) ^*His*^*POL30* cells of the indicated genotypes were synchronised in G1 and released into the cell cycle. Samples were collected at the indicated times and analysed by Ni-NTA affinity chromatogaphy under denaturing conditions, followed by western blotting with PCNA-specific antibody. Asynchronous cultures (AS) were analysed in parallel. (**B**) Cell cycle profiles of the cultures shown in (A), determined by flow cytometry. (**C**) Lethal amounts of DNA damage cause PCNA hyper-sumoylation in *WT*, but not in *pol30-52* cells. Cultures were arrested in G1, S or G2 phase or left asynchronous (AS) and treated where indicated with 0.3% methyl methanesulphonate (MMS) for 90 min. In the right-hand panel, both the *WT* and the *pol30-52* strain (*52*) were treated during exponential growth. Total cell extracts prepared under denaturing conditions were analysed by western blotting using PCNA-specific antibody. The asterisk indicates a cross-reacting band visible with some batches of the antibody. (**D**) DNA damage leads to chromatin association of PCNA outside of S phase. G1 and S phase-arrested cells were treated with 0.3% MMS where indicated. Whole cell extracts (WCEs) were prepared by enzymatic lysis, separated into soluble and chromatin-associated fractions and analysed by western blotting for the presence of PCNA. Phosphoglycerate kinase (PGK) and histone H3 served as controls for soluble and chromatin-associated proteins. Arrests were confirmed by flow cytometry (FACS).](emboj2008162f1){#f1}

![PCNA sumoylation during S phase requires active replication forks. (**A**) *WT* and *cdc7*^*ts*^ cells bearing the ^*His*^*POL30* allele, grown at 25°C, were synchronised in G1 and either kept at 25°C or shifted to 37°C for 90 min before releasing them into the cell cycle at the indicated temperatures. Samples were taken before release (G1) and in mid-S phase (S) according to the budding pattern and Clb2 levels (30 min for *WT* at 25°C and *cdc7*^*ts*^ at both temperatures, 15 min for *WT* at 37°C). PCNA sumoylation was detected as described in [Figure 1](#f1){ref-type="fig"}, Clb2 and PGK were detected in total cell extracts, and the DNA content was monitored by flow cytometry (FACS; dashed line: G1 arrest; solid line: after release). (**B**) Subcellular distribution of Siz1 in *WT* and *cdc7*^*ts*^ cells. Both strains expressing GFP-tagged Siz1 were synchronised in G1 and released into the cell cycle at 25 or 37°C as in (A). Samples were taken at 20-min intervals and analysed by fluorescence microscopy for Siz1--GFP and DNA (DAPI). Representative cells are shown as overlays of fluorescence with interference contrast images. (**C**) Cdc7 kinase is not required for PCNA sumoylation. Modification of ^His^PCNA was analysed in asynchronous cultures of *bob1* and *bob1 cdc7*Δ mutants. The *bob1* mutation affects the *MCM5* gene and renders *CDC7* non-essential.](emboj2008162f2){#f2}

![PCNA sumoylation *in vitro* is stimulated by loading onto DNA. (**A**) *In vitro* sumoylation assays were performed with recombinant Ubc9 and SUMO in the presence or absence of PCNA, E1, RFC, Siz1 and circular, multiply primed ssDNA as indicated. Products were analysed by western blotting with PCNA-specific antibody. (**B**) *In vitro* sumoylation reactions were carried out with the complete set of proteins as in (A), but in the presence or absence of streptavidin (SA) and two different linear DNA structures (I and II) derivatised with biotin on both termini. (**C**) *WT* ^His^PCNA and the trimerisation-deficient protein encoded by the *pol30-52* allele (*52*) were compared in sumoylation assays containing E1, Ubc9, Siz1, SUMO and circular primed ssDNA in the presence or absence of RFC. (**D**) Ubc9- and Siz1-dependent *in vitro* sumoylation of *WT* and mutant (*52*) ^His^PCNA in the absence of DNA. ^His^PCNA was used at 3 μM (compared with 50 nM in A--C).](emboj2008162f3){#f3}

![The Siz1 SAP domain is required for DNA binding. (**A**) Siz1 binds to dsDNA, but not ssDNA. Equimolar amounts of biotinylated DNA fragments of the indicated lengths were immobilised on streptavidin Sepharose, and increasing amounts of ^GST^Siz1^FLAGHis^ were added. Material retained after washing was analysed by western blotting with anti-FLAG antibody. (**B**) Binding to a 76-nt fragment of ssDNA or dsDNA was analysed as above in the presence of 1 mM EDTA. (**C**) Equimolar amounts of the indicated DNA structures were immobilised on streptavidin Sepharose, and Siz1 binding was analysed as above. (**D**) Mutation or deletion of the Siz1 SAP domain results in loss of DNA binding. Equal amounts of Siz1 *WT, SAP\** and *SAP*Δ were analysed on 76mer dsDNA as above.](emboj2008162f4){#f4}

![The Siz1 SAP domain is dispensable for PCNA sumoylation *in vivo*. (**A**) Mutation or deletion of the SAP domain appears to result in partial or complete loss of PCNA sumoylation *in vivo*. Deletion mutants of *siz1* were complemented with integrative plasmids bearing *WT, SAP\** or *SAP*Δ alleles of *SIZ1* or empty vector (−), and modified PCNA was detected in denaturing extracts as described in [Figure 1](#f1){ref-type="fig"}. (**B**) Mutation or deletion of the SAP domain appears to result in partial or complete loss of *SIZ1* function. Sensitivities of the indicated strains to the DNA-damaging agents, methyl methanesulphonate (MMS) and 4-nitroquinoline oxide (NQO) were monitored by growth on plates containing the indicated concentrations of the drugs. Suppression of the damage sensitivity associated with the *rad18* deletion indicates a loss of *SIZ1* function. (**C**) Mutation or deletion of the SAP domain results in loss of the Siz1 protein *in vivo*, which can be rescued by overexpression. The indicated *SIZ1* alleles were expressed from integrative plasmids under control of the *SIZ1* or the galactose-inducible *GAL1* promoter and tagged C-terminally by a 9myc-epitope. An empty plasmid (−) served as a control. Cells were grown in the presence of glucose or galactose, and total extracts were analysed for the presence of Siz1^9myc^ by western blotting. Detection of PGK served as a loading control. (**D**) Overexpression suppresses the sumoylation defects of the *SIZ1* SAP domain mutants. The *SIZ1* constructs shown in (C) were introduced into the ^*His*^*POL30 siz1* strain, and PCNA modifications were analysed as in [Figure 1](#f1){ref-type="fig"} after growth in galactose medium. (**E**) Overexpression of *SIZ1* alleles suppresses the loss of function associated with mutation or deletion of the SAP domain. The *SIZ1* constructs shown in (C) were introduced into *rad18 siz1* strains, and *SIZ1* function was analysed as described for (B) on glucose or galactose plates. (**F**) Expression of the *siz1(SAP*Δ) allele under control of the *CUP1* promoter results in near physiological protein levels. The *CUP1* promoter was induced by growth in 100 μM CuSO~4~, and 9myc-tagged versions of the indicated *SIZ1* alleles were analysed as in (C). (**G**) Expression of *siz1(SAP*Δ) under control of the *CUP1* promoter suppresses the *siz1* phenotype. DNA damage sensitivity assays were carried out with the indicated *SIZ1* alleles in *rad18 siz1* as in (B, E) in the presence or absence of 100 μM CuSO~4~. (**H**) Expression of *siz1(SAP*Δ) under control of the *CUP1* promoter restores PCNA sumoylation *in vivo*. The indicated *SIZ1* alleles were analysed in ^*His*^*POL30 siz1* as in (A, D) in the presence or absence of 100 μM CuSO~4~.](emboj2008162f5){#f5}

![PCNA loading stimulates sumoylation by Siz1 SAP mutants and by Ubc9 alone. (**A**) Mutation or deletion of the Siz1 SAP domain has no effect on PCNA sumoylation in the absence of DNA. *In vitro* sumoylation assays were performed at high substrate concentration (3 μM) with increasing amounts of Siz1 *WT, SAP\** or *SAP*Δ protein. ^GST^Siz1^FLAGHis^ was detected by western blotting with anti-FLAG antibody. (**B**) PCNA loading stimulates sumoylation by Siz1 SAP mutants. *In vitro* sumoylation assays in the presence of RFC and circular primed ssDNA were performed at low substrate concentration (50 nM) with increasing amounts of Siz1 *WT, SAP\** or *SAP*Δ protein (∼1--40 nM). ^GST^Siz1^FLAGHis^ was detected by western blotting with anti-FLAG antibody. (**C**) PCNA loading stimulates E3-independent sumoylation. *In vitro* sumoylation assays in the presence of RFC and circular primed ssDNA were performed with 10-fold elevated concentration of Ubc9 (5 μM). (**D**) PCNA mutants whose interactions with DNA are altered exhibit reduced sumoylation. PCNA modifications *in vivo* were analysed in *WT, pol30(K20A)* and *pol30(K77A)* as described in [Figure 1](#f1){ref-type="fig"}. (**E**) Cell cycle distribution of the *POL30* alleles shown in (D), determined by flow cytometry (FACS).](emboj2008162f6){#f6}
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